Ameritas Investment Partners’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-11,718
| Closed | -$277K | – | 3092 |
|
|
2023
Q4 | $277K | Buy |
11,718
+1,972
| +20% | +$35.1K | 0.01% | 1077 |
|
|
2023
Q3 | $145K | Buy |
9,746
+1,646
| +20% | +$21.8K | 0.01% | 1394 |
|
|
2023
Q2 | $88.7K | Buy |
+8,100
| New | +$75.4K | ﹤0.01% | 1683 |
|
|
2022
Q2 | – | Sell |
-5,958
| Closed | -$19K | – | 3295 |
|
|
2022
Q1 | $19K | Hold |
5,958
| – | – | ﹤0.01% | 2594 |
|
|
2021
Q4 | $20K | Hold |
5,958
| – | – | ﹤0.01% | 2665 |
|
|
2021
Q3 | $22K | Hold |
5,958
| – | – | ﹤0.01% | 2658 |
|
|
2021
Q2 | $26K | Hold |
5,958
| – | – | ﹤0.01% | 2603 |
|
|
2021
Q1 | $27K | Hold |
5,958
| – | – | ﹤0.01% | 2438 |
|
|
2020
Q4 | $34K | Buy |
5,958
+1,040
| +21% | +$7.87K | ﹤0.01% | 2214 |
|
|
2020
Q3 | $36K | Hold |
4,918
| – | – | ﹤0.01% | 2047 |
|
|
2020
Q2 | $17K | Hold |
4,918
| – | – | ﹤0.01% | 2444 |
|
|
2020
Q1 | $7K | Hold |
4,918
| – | – | ﹤0.01% | 2714 |
|
|
2019
Q4 | $10K | Hold |
4,918
| – | – | ﹤0.01% | 2749 |
|
|
2019
Q3 | $25K | Hold |
4,918
| – | – | ﹤0.01% | 2279 |
|
|
2019
Q2 | $35K | Hold |
4,918
| – | – | ﹤0.01% | 2125 |
|
|
2019
Q1 | $65K | Hold |
4,918
| – | – | ﹤0.01% | 1735 |
|
|
2018
Q4 | $39K | Hold |
4,918
| – | – | ﹤0.01% | 1958 |
|
|
2018
Q3 | $54K | Hold |
4,918
| – | – | ﹤0.01% | 1957 |
|
|
2018
Q2 | $66K | Buy |
+4,918
| New | +$61.5K | ﹤0.01% | 1820 |
|
Other funds holding CBAY
Ameritas Investment Partners's CBAY Position: Q1 2024 in Review
Ameritas Investment Partners sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 11,718 shares — an estimated $277K sold.
Ameritas Investment Partners first reported a position in CBAY in Q2 2018 and held it in 19 quarters. The position peaked at $277K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Ameritas Investment Partners reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Ameritas Investment Partners sold 11,718 Cymabay Therapeutics shares in Q1 2024, an estimated $277K.
- Ameritas Investment Partners first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 19 quarters.
- Ameritas Investment Partners's Cymabay Therapeutics position peaked at $277K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Ameritas Investment Partners's 13F filing for Q1 2024, filed 13 May 2024.